IceCure Medical Ltd (NASDAQ:ICCM) Short Interest Update

IceCure Medical Ltd (NASDAQ:ICCM) was the target of a large growth in short interest during the month of November. As of November 15th, there was short interest totalling 2,310,000 shares, a growth of 718.6% from the October 31st total of 282,200 shares. Approximately 10.5% of the shares of the company are short sold. Based on an average daily volume of 677,400 shares, the short-interest ratio is presently 3.4 days.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. HC Wainwright restated a “buy” rating and issued a $2.50 price objective on shares of IceCure Medical in a research note on Wednesday. Alliance Global Partners upgraded shares of IceCure Medical to a “strong-buy” rating in a research note on Friday, November 1st.

Institutional Investors Weigh In On IceCure Medical

An institutional investor recently bought a new position in IceCure Medical stock. Renaissance Technologies LLC acquired a new stake in IceCure Medical Ltd (NASDAQ:ICCM) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 66,400 shares of the company’s stock, valued at approximately $49,000. Renaissance Technologies LLC owned about 0.15% of IceCure Medical at the end of the most recent reporting period. 0.62% of the stock is owned by hedge funds and other institutional investors.

IceCure Medical Stock Performance

ICCM stock traded up $0.05 during trading hours on Wednesday, hitting $0.84. 488,833 shares of the stock were exchanged, compared to its average volume of 581,835. The company has a 50-day simple moving average of $0.64 and a two-hundred day simple moving average of $0.72. The firm has a market capitalization of $38.32 million, a P/E ratio of -2.70 and a beta of 0.48. IceCure Medical has a 12 month low of $0.48 and a 12 month high of $1.57. The company has a current ratio of 2.97, a quick ratio of 2.54 and a debt-to-equity ratio of 0.03.

IceCure Medical Company Profile

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.